| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Internal Medicine, Korea University Hospital, 516 Kojan-Dong, Ansan City, Kyungki-Do 425-020, Korea
1 Department of Internal Medicine and Biochemistry, College of Medicine, Korea University, Ansan City, Kyungki-Do, Korea
2 Department of Internal Medicine, College of Medicine, Inje University, Ilsan-Gu, Koyang City, Kyungki-Do, Korea
3 Department of Internal Medicine, College of Medicine, Yonsei University, Seodaemun-Gu, Seoul, Korea
(Requests for offprints should be addressed to D R Cha; Email: cdragn{at}unitel.co.kr)
Angiotensin II (Ang-II) and vascular endothelial growth factor (VEGF) have an important role in the pathogenesis of diabetic nephropathy, but the signaling cascade of VEGF regulation in response to Ang-II in podocytes is largely unknown. In these experiments, we looked at the effect of Ang-II on the production of VEGF, and investigated whether VEGF production depends on the p38 mitogen activated protein kinase (MAPK) pathway in cultured mouse podocytes. Incubation of podocytes with Ang-II induced a rapid increase in VEGF mRNA expression and protein synthesis as well as its transcriptional activity in an Ang-II dose-dependent manner. To further define the role of angiotensin type 1 (AT1) and type 2 (AT2) receptors involved in Ang-II-mediated VEGF synthesis, the effects of selective AT1 and AT2 receptor antagonists were evaluated. Prior treatment with losartan significantly inhibited VEGF mRNA and protein synthesis induced by Ang-II, which suggests that the AT1 receptor is involved in Ang-II-mediated VEGF synthesis. Furthermore, stimulation of the cells with Ang-II increased both phosphorylation of p38 MAPK and MAP kinase kinase 3/6 (MKK3/6). Additionally, Ang-II enhanced the DNA binding activity to cAMP response element binding protein (CREB) and phosphorylation of CREB. In addition, to investigate the role of p38 MAPK in Ang-II-induced VEGF synthesis, podocytes were pretreated with or without the p38 MAPK inhibitor, SB203580 for 24 h to observe whether Ang-II-mediated VEGF synthesis was inhibited by blocking p38 MAPK. The addition of SB203580 led to a marked inhibition of the increased VEGF mRNA and protein production induced by Ang-II in a dose-dependent manner. Taken together, these results suggest that Ang-II stimulates the synthesis of VEGF in podocytes and the production of VEGF induced by Ang-II is mediated, in part, through the activation of the p38 MAPK pathway.
This article has been cited by other articles:
|
|
 |
|
  T. Onguchi, K. Y. Han, J.-H. Chang, and D. T. Azar Membrane Type-1 Matrix Metalloproteinase Potentiates Basic Fibroblast Growth Factor-Induced Corneal Neovascularization Am. J. Pathol., April 1, 2009; 174(4): 1564 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Vieitez, O. Gomez, E. R Uceda, M. E. Vera, and E. Molina-Holgado Systemic and local effects of angiotensin II blockade in experimental diabetic nephropathy Journal of Renin-Angiotensin-Aldosterone System, June 1, 2008; 9(2): 96 - 102. [Abstract] [PDF]
|
|
|
|
 |
|
 D. J. Kelly, D. Buck, A. J. Cox, Y. Zhang, and R. E. Gilbert Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy Am J Physiol Renal Physiol, August 1, 2007; 293(2): F565 - F574. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
